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emerged as attractive vehicles for improved therapy. In 
addition to being used as tools for molecular imaging they 
also could deliver therapeutic agents to the injury site, thus 
allowing simultaneously imaging and therapy, called ther-
agnosis. [ 2,3 ] Such nanoparticulate systems should enable 
appropriate residence time in blood stream, long enough 
as to afford delivery of the drug and/or diagnostic probes 
at target site, at the same time allowing its complete elimi-
nation within an acceptable timeframe, in order to avoid 
toxicity or chronic effects. [ 4,5 ] Unfortunately, many types 
of systemically injected NPs have a rapid blood clearance, 
essentially due to the action of the mononuclear phago-
cytic system mainly at the liver, spleen, lung, and bone 
marrow. So, NPs formulation that avoids rapid clearance is 
a requirement for suitable delivery to the desired target. [ 5 ] 
 In a previous study we reported the synthesis of a glycol 
chitosan (GC) nanogel functionalized with folate with 
an average size of 200 nm and positive surface charge 
 The preclinical development of nanomedicines raises several challenges and requires a com-
prehensive characterization. Among them is the evaluation of the biodistribution following 
systemic administration. In previous work, the biocompatibility and in vitro targeting ability 
of a glycol chitosan (GC) based nanogel have been validated. In the present study, its biodis-
tribution in the mice is assessed, using near-infrared (NIR) ﬂ uorescence imaging as a tool to 
track the nanogel over time, after intravenous administration. Rapid whole body biodistri-
bution of both Cy5.5 labeled GC nanogel and free polymer is found at early times. It remains 
widespreadly distributed in the body at least up to 6 h postinjection and its concentration then 
decreases drastically after 24 h. Nanogel blood circulation half-life lies around 2 h with the 
free linear GC polymer presenting lower blood clearance rate. After 24 h, the blood NIR ﬂ uo-
rescence intensity associated with both samples decreases to 
insigniﬁ cant values. NIR imaging of the organs shows that the 
nanogel had a body clearance time of ≈48 h, because at this 
time point a weak signal of NIR ﬂ uorescence is observed only 
in the kidneys. Hereupon it can be concluded that the engi-
neered GC nanogel has a fairly long blood circulation time, 
suitable for biomedical applications, namely, drug delivery, 
simultaneously allowing efﬁ cient and quick body clearance. 
 In Vivo Imaging of Glycol Chitosan-Based 
Nanogel Biodistribution 
 Paula  Pereira ,  Alexandra  Correia ,  Francisco M.  Gama* 
 P. Pereira, F. M. Gama 
 Centre of Biological Engineering 
 University of Minho 
 Campus de Gualtar,  4710-057  Braga ,  Portugal
E-mail: fmgama@deb.uminho.pt 
 A. Correia 
 I3S - Instituto de Investigação e Inovação em Saúde
Universidade do Porto and IBMC - Instituto de Biologia 
Molecular e Celular
Rua do Campo Alegre, 4099-003 Porto, Portugal 
 1.  Introduction 
 The use of engineered nanoparticles (NPs) in nanomedicine 
is revolutionizing the clinical practice, regarding both diag-
nosis and therapy. [ 1 ] Due to their multifunctional nature, 
large surface area, structural diversity, and long vascular 
circulation time (as compared to small molecules), NPs have 
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(+25 mV). [ 6 ] In vitro assays conﬁ rmed ability for folate 
receptors targeting and also the efﬁ cient encapsulation 
of siRNA. Few studies of chitosan based NPs biodistribu-
tion are available in literature, most of which are focused 
on anti-tumor efﬁ cacy of a drug loaded NP. [ 7 ] Thus in the 
current work we intend to show an assessment of the GC 
nanogel biodistribution in a mice model, using optical 
ﬂ uorescence imaging technology. Near-infrared (NIR) 
based imaging, in addition to enabling noninvasive study 
of molecular targets inside the body of the living animal, 
is versatile, easy-of-use, avoids the use of radiopharma-
ceuticals, and has a relatively low cost. [ 8,9 ] The NIR probe 
Cy5.5 was chosen to label the nanogel as well as the free 
polymer. Fluorophores with a red or NIR emission range 
(600–1000 nm) bear a high photon penetration into living 
tissues, and low photon absorption and tissue autoﬂ uores-
cence, thus allowing effective imaging of deep tissues. [ 10,11 ] 
 2.  Experimental Section 
 Materials : GC (G7753,  M w = 100 kDa), mercapto hexadeca-
noic acid (MHDA),  N -hydroxysulfosuccinimide (NHS), 1-Ethyl-
3-[3-dimethylaminopropyl]carbodiimide hydrochloride, folate, 
O-methyl-O′-succinylpolyethyene glycol 2000 (PEG2000), and 
O-(2-Aminoethyl)-O′-(2-carboxyethyl)polyethylene glycol 3000 
hydrochloride (PEG3000) were acquired from Sigma-Aldrich (St. 
Louis, MO, USA). Cy5.5 monoreactive NHS ester was purchased 
from GE Healthcare (Little Chalfont, UK). 
 Synthesis and Self-Assembly of GC Nanogels : Details on the 
synthesis of the GC nanogel synthesis and its decoration with 
folic acid were described in a previous report. [ 6 ] Brieﬂ y, nanogel 
synthesis was performed in two independent steps. Initially, 
folate was conjugated to PEG3000 (FA-PEG3000). In the second 
reaction, FA-PEG3000, PEG2000, and MHDA were grafted onto the 
GC polymer. The nanogel colloidal suspensions were obtained 
after dispersing the lyophilized reaction product in saline buffer 
(PBS), under magnetic stirring at 50 °C for 48 h, and ﬁ ltration 
through a pore size 0.45 μm cellulose acetate syringe ﬁ lter. 
 In Vitro Evaluation of Nanogel Serum Stability : The nanogel 
serum stability was assessed by incubating the nanogel at a 
concentration of 1 mg mL −1 in PBS with 1% (v/v) of fetal bovine 
serum (FBS), under constant stirring at room temperature. At 
predeﬁ ned time points (0, 2, and 24 h) the samples size distribu-
tion was monitored by DLS using a Malvern Nano ZS instrument 
(Malvern Instruments). 
 Preparation of GC and Nanogel Cy5.5 Conjugation : Free 
polymer and nanogels were labeled with an NIR ﬂ uorescent 
probe, Cy5.5 monoreactive NHS ester. The chemical structure of 
Cy5.5 conjugated with nanogel is shown in Scheme  1 . The dye 
solution (10 mg mL −1 , in DMSO) was added to GC or nanogel 
dispersion (1 mg mL −1 , in PBS) at 0.04 and 0.06 molar ratios of 
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 Scheme 1.  Representation of the chemical structure of Cy5.5 conjugated with nanogel.
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Cy5.5 reactive carboxylic groups to GC or nanogel free amine 
groups, respectively. The reaction was allowed to occur for 
24 h in the dark at room temperature. Thereafter, the reaction 
mixture was extensively dialyzed ( M w cutoff 10–12 kDa) against 
distilled water to remove unreacted Cy5.5 molecules. To conﬁ rm 
the absence of free dye, Cy5.5-GC or Cy5.5-Nanogel was puri-
ﬁ ed by centrifugation at 3000 × g through a 10 kDa  M w cutoff 
ﬁ lter. Then, Cy5.5 was quantiﬁ ed spectrophotometrically in the 
resultant fractions (ﬁ ltrate and concentrate). 
 In Vivo Biodistribution of GC and GC Nanogels : The animal 
experiments were performed in agreement and approved 
by IMM (Institute of medicine and Molecular, Lisbon, Por-
tugal) Animal Ethics Committee and Portuguese General 
Alimentary and Veterinarian Board (authorization number 
006315/27/03/2014, from DGAV-Portugal). Male BALB/c mice, 
eight weeks old (Charles River, L’Arbresle, France), were used for 
animal experiments. 5 mg Kg −1 of Cy5.5-GC or Cy5.5-Nanogel 
was intravenously injected via the tail vein. After injection, the 
time-dependent in vivo samples biodistribution were noninva-
sively imaged with mice anesthetized with Ketamine 75 mg kg −1 
BW and Medetomidine 1 mg Kg −1 BW solution, using the IVIS 
Lumina ﬂ uorescence imaging system. 
 For the imaging study, exposure time (3 s), pixel binning (CCD 
resolution, medium), and lens aperture (amount of light collected 
and depth-of-ﬁ eld, f/stop 16) were optimized. The NIR ﬂ uores-
cence signal intensity of each of the Cy5.5 labeled samples on 
respective injected animals was imaged using a CCD camera 
equipped with a Cy5.5 bandpass emission ﬁ lter (680–720 nm). 
The obtained results were resultant from two independent 
experiments, with consistent results being obtained. Since only a 
qualitative analysis of the results was performed, it was decided 
not to perform additional replicates. 
 Fluorescence Intensity Measurement in the Blood and Dif-
ferent Organs : At the end of each time point whole blood (about 
0.8 mL) was collected from anesthetized animals using cardiac 
puncture. Immediately after, they were sacriﬁ ced through cer-
vical dislocation to collect the organs of interest: the spleen, 
heart, liver, kidneys, brain, lungs, muscle, and skin. Blood and 
organs were placed in a 6-well plate for IVIS Lumina ﬂ uores-
cence imaging system visualization. The semi-quantiﬁ cation of 
NIR ﬂ uorescence signal in different organs and blood acquired 
images was performed using a Living image software and meas-
ured as total photons per centimeter squared per steradian 
(p s −1 cm −2 sr −1 ). 
 3.  Results and Discussion 
 3.1.  Nanogel Serum Stability 
 It is known that positively charged particles (such as GC 
nanogel, which has a potential zeta of +25 mV [ 6 ] easily 
induce nonspeciﬁ c interactions with serum proteins, 
which can contribute to nanogel colloidal disassem-
bling, rapid blood clearance, and also to opsonization and 
liver accumulation. [ 12,13 ] The assessment of GC nanogel 
interaction with FBS was studied by dynamic light 
scattering. As can be observed in Figure  1 , the nanogel 
showed colloidal stability and constant size in the pres-
ence of FBS, even after 24 h of incubation. Indeed, the 
nanogel average size, around 200 nm, remained con-
sistent over the time. It can also be seen that serum pro-
teins are somewhat unstable, likely due to aggregation, as 
noted by the shift toward a higher size distribution. This 
result emphasizes the absence of extensive interaction 
between nanogel and serum components, probably due to 
its PEG functionalization, since it is well-known the ability 
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 Figure 1.  Nanogel size stability in the presence of serum assessed 
by DLS over the time.
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of PEG to minimize nonspeciﬁ c proteins adsorption and 
aggregation. [ 14 ] 
 3.2.  GC and Nanogel Labeling 
 CyDyes are commonly used in a wide range of biological 
assays. Cy5.5 has been used historically for imaging, 
even though its excitation/emission wavelengths 
(675/694 nm) are very close to the wavelength range 
(400–650 nm, visible spectrum) which is affected by tissue 
autoﬂ uorescence. [ 15,16 ] In order to comparatively study 
the in vivo biodistribution of the unmodiﬁ ed GC and its 
derived nanogel, Cy5.5 monoreactive ester was chosen to 
label both samples. The comparison is only possible if sam-
ples were similarly labeled. Therefore, a theoretical molar 
ratio of 4% and 6% of Cy5.5 reactive carboxylic groups 
in regard to the free amine groups, respectively for the 
GC polymer and its nanogel, was experimentally observed 
to provide a similar Cy5.5 labeling, as shown in Figure  2 . 
Indeed, the resulting ﬂ uorescence signal obtained in the 
different samples is comparable. 
 The lack of unconjugated Cy5.5 in the labeled GC 
and nanogel was also assessed spectrophotometrically. 
Basal absorbance was recorded using the ﬁ ltered frac-
tion obtained following ultraﬁ ltration, thus demon-
strating that all of the conjugate is properly grafted on the 
polymer (data not shown). 
 3.3.  Unconjugated Cy5.5 Biodistribution 
 The biodistribution/body clearance proﬁ le of free 
Cy5.5 was assessed 6 h post administration. Whole body 
imaging showed that free Cy5.5 was distributed to little 
extension, as compared to conjugated dye (Figure  3 A), indi-
cating faster body clearance. Negligible NIR ﬂ uorescence 
was detected in the blood, spleen, heart, kidneys, and brain 
(Figure  3 B,C) using the free dye, a weak signal being found 
in the lungs, muscle, and liver. Remarkably, 6 h after injec-
tion an intense NIR ﬂ uorescence signal was observed in 
the skin, as also observed in animals treated with Cy5-5-GC 
or nanogel. Hue et al. [ 17 ] found that Cy5.5 ﬂ uorescence in 
several organs was rapidly eliminated from 30 min to 24 h 
postinjection, fairly high ﬂ uorescence signal being reached 
in the liver, lung, kidneys, and stomach at the early time 
points. 
 3.4.  Cy5.5-GC and Cy5.5-Nanogel Biodistribution 
 3.4.1.  Whole Body Biodistribution 
 It is known that autoﬂ uorescence naturally occurs in 
animal tissues through the visible spectral range up to 
700 nm, which may mask the probe signal. [ 15 ] Hence, this 
feature was taken into consideration and system image 
acquisition parameters were optimized using a nonin-
jected mouse (Cont-). As could be observed in Figure  4 , no 
interference of tissues autoﬂ uorescence was visualized 
under the used conditions. So, the NIR ﬂ uorescence signal 
detected by a CCD camera is exclusively associated with 
Cy5.5. 
 In order to observe in vivo biodistribution of Cy5.5-GC 
and Cy5.5-Nanogel, a 5 mg Kg −1 dosage of the samples 
homogenously dispersed in 100 μL of PBS was intrave-
nously administered into the tail vein of BALB/c mice. 
A time-dependent distribution was observed using a 
noninvasive NIR ﬂ uorescence imaging technique in live 
animals, as shown in Figure  4 . An intense NIR ﬂ uores-
cence signal was observed in the whole body 15 min only 
after injection (reﬂ ecting the rapid sample biodistribu-
tion), the signal remaining intense for at least 6 h. The 
ﬂ uorescence signal fades drastically after 24 h postinjec-
tion. It is noteworthy that a strongest ﬂ uorescent signal 
was observed on the mice treated with Cy5.5-Nanogel 
and the distribution pattern clearly progresses from a 
widespread distribution at early time points to a more 
posterior concentrated distribution (kidneys and bladder) 
in a later stage, showing the predictable fate of the 
sample, its elimination by ﬁ ltration. Likewise, in a similar 
study, the biodistribution proﬁ le of NPs of a  N,N -diethyl-
nicotinamide-based oligomer conjugated with GC showed 
high NIR ﬂ uorescent signal 1 h after injection, which was 
preserved for up to 1 d, followed by a reduction. [ 18 ] 
 3.4.2.  Blood Clearance 
 One of the major design considerations for nanoparticulate 
drug delivery systems is the circulation half-life, since the 
longer this is the more effectively the NPs may accumulate 
at the target site, either by passive or active mecha-
nisms. [ 19 ] Thus, in order to study the blood half-life, whole 
blood was collected from mice injected with the samples at 
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 Figure 2.  Absorbance spectral scans of Cy5.5, free and conjugated 
with GC or GC nanogel four times diluted as compared to injected 
samples.
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different time points and scanned using the IVIS Lumina 
system (Figure  5 ). NIR ﬂ uorescence intensity of whole 
blood in each condition was semi-quantiﬁ ed using Living 
image software and expressed as average radiance. Liu 
et al. [ 10 ] classify the ﬂ uorescence imaging as a semi-quanti-
tative technique, as they proved that the quantitative data 
from whole organs are strongly affected by the scattering 
and the absorption properties of the organ. Therefore the 
ﬂ uorescence intensity detected may not necessarily be 
proportional to the number of molecules present, and thus 
the results are here discussed qualitatively. 
 The Cy5.5-Nanogel exhibited a fairly long blood circu-
lation half-life, about 2 h, which is compatible with the 
general aim of addressing NPs to a particular tissue in 
the body. Nevertheless, the NIR ﬂ uorescence intensity 
signal decays faster at the initial stage after administra-
tion, probably due to kidneys ﬁ ltration and retention in 
the organs. Surprisingly, GC polymer presented a higher 
blood circulation half-life, being detected in signiﬁ cantly 
higher intensity than the nanogel 6 h postinjection. 
In both cases, however, 24 h after administration only 
a residual amount is detectable. Apparently, the free 
polymer is thus more effective in evading the mononu-
clear phagocytic system. Foreign entities in bloodstream 
circulation are generally marked for uptake by mono-
nuclear phagocytic system, through a process known 
as opsonization. Particles functionalized with PEG, or 
other hydrophilic polymers, have increased circulation 
half-life because they are shielded with water molecules, 
remaining invisible to opsonins and macrophages. [ 5,19 ] 
Hence, lower circulation half-life of the GC nanogel 
comparatively to free polymer was unexpected, since 
the nanogel was decorated with PEG chains of 2000 and 
3400 Da, whose ability for prolonging circulation time in 
blood is well reported. [ 20,21 ] On the other hand, the size of 
the nanogel is much higher than that of the GC polymer. 
The GC used in this work has a molecular weight ( M w ) 
of 100 kDa, expected to correspond to a hydrodynamic 
size of a few nanometers, while the nanogel has about 
200 nm. Hence a faster kidney ﬁ ltration would be 
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 Figure 3.  Biodistribution of unconjugated Cy5.5 as compared with Cy5.5 conjugated with GC or nanogel, in BALB/c mice 6 h postintravenous 
injection. A) NIR imaging of whole body, B) total blood, and C) ex vivo organs (1: spleen; 2: heart; 3: liver; 4: kidneys; 5: brain; 6: lungs; 7: 
muscle; and 8: skin).
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expectable for the polymer. The larger size could on the 
other hand justify a more effective recognition of the 
nanogel by macrophages (although decorated with PEG) 
as the results consistently show the GC polymer has a 
longer blood circulation time. However, the accumula-
tion of the nanogel in the liver, although occurring to 
larger extent than the free polymer, is only transient, as 
discussed below. 
 Also N-succinyl-chitosan was reported as a systemi-
cally long circulating polymer. The retention of succinyl-
chitosan in blood was much higher than that in other 
tissues even at 72 h after injection. The half-life was cal-
culated to be around 100 h. Kato et al. argued that this 
longer retention was probably due to high  M w (>700 kDa), 
difﬁ cult biodegradation, and poor interaction with tissues 
due to its high negative charge, differently from the here 
analyzed nanogel. [ 22 ] 
 Controversially, Richardson et al. reported rapid blood 
clearance for three tested samples of chitosan with dif-
ferent  M w (<5, 5–10, and >10 kDa). In this study, 1 h after 
injection only 2.6% of the radiolabeled chitosan ( 125 I) with 
>10 kDa remains in the blood. [ 23 ] Na et al. [ 24 ] veriﬁ ed that 
GC NPs synthesized with increasing degrees of substitu-
tion of 5β-cholonic acid had higher blood circulation time 
compared to the GC linear polymer, whose ﬂ uorescence 
intensity decreased 1 d postinjection. Also Kim et al. [ 25 ] 
found that Cy5.5 and Cy5.5 labeled GC were excreted 
from body within 1 d, while hydrophobically modiﬁ ed 
GC takes 3 d. 
 3.4.3.  Organs Biodistribution 
 In order to evaluate the nanogel and linear GC organ distri-
bution at deﬁ ned time points, the organs were excised and 
imaged in the IVIS Lumina system. NIR ﬂ uorescence inten-
sity of each organ was semi-quantiﬁ ed using Living image 
software and expressed as average radiance. Overall, 
GC nanogel shows higher tissue accumulation at earlier 
time points ( t = 15 min and  t = 2 h), mainly in the lungs 
and skin (highly vascularized organs) as compared to free 
polymer, as could be observed in Figure  6 A,B. This obser-
vation is consistent with the shorter circulation half-life of 
the nanogel. Again, this is somewhat surprising, since the 
positive charges of the free polymer would be expected to 
Macromol. Biosci. 2016,  16,  432−440
 Figure 4.  Representative experiment of whole body NIR ﬂ uorescence images of Balb/C mice intravenously injected with Cy5.5-GC and 
Cy5.5-Nanogel (5 mg Kg −1 ), observed over time.
 Figure 5.  Blood circulation half-life of GC and nanogel. A) Representative NIR ﬂ uorescent images of whole blood collected over time 
after intravenous injection of Cy5.5-GC and Cy5.5-Nanogel samples in BALB/c mice. B) NIR ﬂ uorescence intensity signal quantiﬁ cation of 
Cy5.5 labeled samples.
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interact with cells more readily than the nanogel, which 
is decorated with PEG. Maybe the folate receptor plays 
therefore a relevant role and it may be responsible for 
the quicker retention of the nanogel in the tissues. 24 h 
postinjection, when no GC or nanogel was observed in 
blood anymore, a similar organ distribution pattern was 
observed for both samples, exception made to higher accu-
mulation of the free polymer in the lungs and kidneys, as 
observed in NIR images (Figure  6 C). For later postinjection 
periods (48 h) higher NIR ﬂ uorescence signal was found 
in the organs of mice injected with linear GC as compared 
to nanogel, which barely was found, with exception to 
the kidneys. The nonspeciﬁ c interaction of the free GC 
with cells seems to retard the excretion to some extent, 
 Figure 6.  Ex vivo NIR ﬂ uorescence imaging of Cy5.5-GC and Nanogel organ biodistribution. A,B) Quantiﬁ cation of NIR ﬂ uorescence signal of 
Cy5.5-GC or Nanogel (respectively) organs accumulation at different time points, recorded as total photon counts per centimeter squared 
per steradian (p s −1 cm −2 sr −1 ) per excised organ as a function of time. C) Representative ex vivo images of normal organs (1: liver; 2: kidneys; 
3: lungs; 4: muscle; and 5: skin) acquired over time after Cy5.5-GC or Nanogel intravenous injection. Organs of noninjected mice were used 
as negative control of NIR ﬂ uorescence.
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as compared to the speciﬁ c interactions mediated by the 
folate receptor. Localization of the nanogel and GC polymer 
in the kidneys is expected and common to other chitosan 
NPs because they play an important role in the clear-
ance of biodegradable macromolecules circulating in the 
bloodstream. [ 25–27 ] So, 48 h postinjection almost all of the 
injected nanogel was almost fully eliminated, which repre-
sents a great prospect concerning toxicity issues. This body 
clearance behavior suggests that the nanogel disassembles 
in vivo, being excreted in about 2–3 d. This is particularly 
important due to concerns over long-term exposure. [ 4 ] The 
in vitro biocompatibility of this nanogel was reported in 
our previous manuscript. [ 28 ] According to published works, 
the conjugated Cy5.5 should not bring about toxic-related 
issues. [ 29,30 ] 
 It should be noted that NIR signal fadeout corresponds 
indeed to the excretion of the conjugated dye, and not 
to the dye instability, or loss of signal over time. As a 
matter of fact, similar studies such as biodistribution of 
Cy5.5 labeled chitosan coated iron oxide NPs showed high 
signal intensity for at least 72 h in the kidneys, spleen, 
liver, and bone marrow. [ 5 ] Based on this observation, an 
interesting approach for kidneys targeted drug delivery 
was developed by Gao et al. [ 31 ] They reported for the ﬁ rst 
time the use of chitosan/siRNA NPs for extended siRNA 
accumulation in the kidneys, which may have potential 
for treatment of renal diseases using RNAi therapeutics. 
 Curiously, in spite of the liver, spleen, and lung being 
important components of the mononuclear phagocytic 
system and consequently involved in macromolecules 
clearance, in the current study nanogel and even free 
GC were poorly taken up by the liver and spleen, unlike 
described by other authors. [ 5,32 ] 
 Nevertheless also He et al. [ 33 ] veriﬁ ed that rhodamine 
B labeled chitosan hydrochloride distribution in spleen 
decreased with the increase of the particle size from 
150 to 300 nm, which was probably due to the splenic 
physical ﬁ ltration effect that excluded NPs with particle 
size ranging in 200–500 nm. Indeed, the size distribution 
of the GC nanogel studied in the present work lies within 
this range, so it could be predicted that this nanogel with 
an average size of 220 nm would show minor accumula-
tion in the spleen. 
 Lungs, together with skin, is one of the organs where 
higher nanogel accumulation was found 24 h postad-
ministration, as also the free polymer—although to less 
extent in this case. He et al. [ 33 ] assigned the higher con-
centration of rhodamine B labeled chitosan hydrochlo-
ride in the lungs to the high positive charge, which would 
lead to the NPs forming aggregates with blood cells by 
electrostatic interaction, consequently being entrapped 
in the lungs. Also Knudsen et al. [ 34 ] found that cationic 
liposomes after intravenous administration were pref-
erentially distributed to the lungs. Sykes et al. [ 35 ] also 
showed that skin is an important site of NPs accumula-
tion following systemic administration. Their results 
suggest that dermal accumulation should be exploited 
to trigger the release of ultraviolet and visible light-sensi-
tive therapeutics which are currently impractical in vivo. 
Nevertheless, further tests should be performed in order 
to clarify whether the GC and nanogel skin accumulation 
24 h postinjection are independent of the dye, because 
as shown ahead in Figure  3 fairly high NIR ﬂ uorescence 
intensity was observed in this tissue 6 h after free dye 
administration. 
 4.  Conclusion 
 The rapid biodistribution of GC nanogel and linear GC 
labeled with Cy5.5 was readily observed through in vivo 
NIR imaging system. Whole body images acquisition pro-
vides an overview on the extension of sample biodistri-
bution, however it is the whole blood and organs analysis 
that renders more accurate information on nanogel blood 
clearance, organs accumulation, and consequently also on 
the body clearance. In summary, it could be concluded that 
the nanogel has a blood clearance rate superior to that of 
the free polymer. Even so, the nanogel exhibits a satisfac-
tory blood circulation half-life of about 2 h and its body 
clearance occurs ≈48 h after administration. 
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